MDX Medical Inc.

MDX Medical Inc.

April 10, 2006 09:00 ET

MDX to Develop a Non-Invasive Urodynamics Device

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 10, 2006) - MDX Medical Inc. (TSX VENTURE:MDX) announced today it has commenced development of a non-invasive urodynamics device. MDX's NIU device is a breakthrough in bladder care providing non-invasive monitoring and diagnosis of bladder dysfunction including urinary incontinence, which affects over 3.3M Canadians and 25M Americans.

World Health Organization & the US National Institutes for Health estimates that urinary incontinence affects 200M people worldwide and estimates disease costs in the US at $16B annually. This condition, when properly diagnosed and assessed, can be treated effectively.

This research is being supported with assistance from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) which includes a contribution of $253,924 towards the costs of the development of the technology, which is expected to be over a 12 month period.

The contribution will assist MDX in accelerating the commercialization of the technology, which was licensed from the University of British Columbia (UBC).

Barry Allen, President and Chief Executive Officer, said, "This contribution encourages our efforts and will allow MDX to enhance the development of its NIU device and bring this exciting technology to the market on schedule."

About MDX Medical:

MDX Medical Inc. (MDX-V) is an early stage medical device Company focused on the development and commercialization of breakthrough diagnostic technology for bladder conditions specifically Urinary Incontinence. MDX is currently developing a family of non-invasive diagnostic and monitoring technologies for these conditions which affects over 3.3M Canadians and 25M Americans. For more information about MDX, please visit our website at:


Recognized globally for research and innovation, NRC is a leader in the development of an innovative, knowledge-based economy for Canada through science and technology.

NRC-IRAP provides a range of both technical and business oriented advisory services along with potential financial support to growth-oriented Canadian small and medium-sized enterprises. The program is delivered by an extensive integrated network of 260 professionals in more than 100 communities across the country. Working directly with these clients, NRC-IRAP supports innovative research and development and commercialization of new products and services. For additional information, please visit

On behalf of the Board,

Barry Allen, President & CEO

MDX Medical Inc.

Certain information contained in this press release may be forward looking and is subject to unknown risks, which could cause actual results to differ materially from those, set forth or implied herein. Although the Company believes that the expectations reflected in such forward looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information